CO2_2016 - page 39

NEWS NEWS NEWS NEWS NEWS
NEWS
NEWS
High-Content
Screening Conference
12–13 April 2016,
Wyndham Garden Hotel,
Berlin, Germany
europe-slas.org
27–29 June 2016,
Max Planck Institute of Molecular
Cell Biology and Genetics,
Dresden, Germany
Compound
Management Co
nference
in Industry and Academia
CORDENPHARMA ANNOUNCES EXPANDED ASEPTIC AND ORAL DEVELOPMENT CAPABILITIES IN ITS MANUFACTURING NETWORK
As part of a long term strategy to meet increasing customer demands,
CordenPharma
has completed two additional key
investments to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly
Potent, Oncology and Injectables Platforms.
Firstly, CordenPharma is pleased to announce the completion and approval of its small-scale aseptic filling line in
CordenPharma Caponago
(IT). This addition to the existing terminal sterilization capabilities of the manufacturing facility
will support customer development and commercial programs by providing expert service in aseptic-filling of liquid and
lyophilized vials and pre-filled syringes for small molecules and peptides.
CordenPharma is additionally pleased to announce the completion and approval of expanded Development Capabilities
(CTD2) for mid-scale (up to 20 kg) contained capacity of highly potent and oncology oral dosage forms in its CordenPharma
Plankstadt
(DE) manufacturing facility. This new and expanded capability provides customers a complete offering in the
contained manufacturing of oral dosage from grams to 150 Kg.
Ernesto Petroselli,
President of CordenPharma International
comments, “These new investments in oral and aseptic
development capacities strengthen our ability to serve customers earlier in the pharmaceutical value chain. They are a clear
indication of our overall commitment in responding to customers’ needs and are perfect complements to our existing API and
Drug Product service offerings within our Highly Potent, Oncology and Injectables Platforms.
In addition, we anticipate further capacity expansion in the second half of 2016 by the completion of a second
pharmaceutical oncology suite in
CordenPharma Latina
(IT) to provide
extended supply chain manufacturing
services spanning development to
commercial scale.”
These expansions enhance
CordenPharma’s service offerings in the
sterile and containment fields spanning
from development to well-established
worldwide commercial supply.
1...,29,30,31,32,33,34,35,36,37,38 40,41,42,43,44,45,46,47,48,49,...68
Powered by FlippingBook